Skip to main content
Premium Trial:

Request an Annual Quote

Abbott's Q1 MDx Sales Increase 6 Percent

NEW YORK (GenomeWeb News) – Abbott today reported that its first-quarter molecular diagnostics sales increased 6 percent year over year as its total sales were up around 5 percent compared to Q1 2011.

Abbott reported molecular diagnostics sales of $105 million, up from $99 million for the first quarter of 2011. Of that total, $47 million came from the US market and $58 million in sales were derived from international markets.

The firm said that it expects to launch more than 15 new molecular diagnostic products over the next few years, including cancer and infectious disease tests.

Overall, Abbott reported sales of $9.46 billion for the first quarter, up around 5 percent from $9.04 billion for Q1 2011. Its net earnings increased to $1.24 billion, or $.78 per share, from $864 million, or $.55 per share.

The firm raised its FY 2012 EPS guidance to a range between $5.00 and $5.10 from $4.95 and $5.05.

Abbott said in October that it intends to split the company into two publicly-traded companies — one focused on diversified medical products and the other on research-based pharmaceuticals. Today, it said that it expects to complete the split by the end of this year.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.